CTLA4 and melanoma: In vivo, GM-CSF cell-based vaccines (GVAX) plus anti-CTLA-4 antibody has shown synergistic impacts in attenuating tumor size and restoring the antitumor immune reactions in melanoma [233] and also prostate [234] mice model.